She walks through research in adults with type 2 diabetes and excess weight that asked whether losing more weight leads to a healthier liver.
Recap by typeshit. Post by @doctormekhala on Instagram.
6:25
Dr Almerie compares Lilly's experimental retatrutide with Mounjaro and talks through the case for switching versus holding off until it's approved.
He points to GLP-1 receptors in the hypothalamus, saying the medication boosts fullness signals and slows the stomach, which changes how hunger feels.
10:08
Weight loss doctor Bazgha Khalid goes through what the published trials actually show for Zepbound against Lilly's newer retatrutide.
Patients who took a GLP-1 receptor agonist before surgery did not lose more weight at one year, JAMA Surgery reports. The full study has the details.
Some users count clicks on their pens to take smaller doses, hoping to ease side effects and costs. Experts weigh in on whether it's safe.
The lineup includes low-dose CagriSema results from REDEFINE 9, real-world Wegovy pill data, and full STEP Young results in children ages 6 to under 12.
Loading…